Unlocking pathways to be
Compass Pathways (compasspathways.com) earns a Brand Analyzer score of 86 out of 100, placing it in the Strong Brand tier among Healthcare brands. Among 4155 Healthcare brands analyzed, Compass Pathways ranks in the 93rd percentile (category average 73, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 78/100, Digital Presence 100/100, Visual Identity 93/100, Messaging Clarity 95/100, Trust Foundation 94/100, AI Discoverability 84/100, Brand Authority 61/100.
Compass Pathways is a British biotechnology company, founded in 2016 and headquartered in London, that develops psilocybin-based treatments for difficult-to-treat mental health conditions. The company combines clinical research with a compassion-driven approach to create new treatment options where existing mental health care falls short. It works with patients, caregivers, and healthcare professionals to advance psychedelic therapy as a potential new clinical standard for chronic mental health disorders.
| Brand Name | Compass Pathways |
|---|---|
| Domain | compasspathways.com |
| Industry | Healthcare |
| Founded | 2016 |
| Headquarters | London |
| Main Competitors | MindMed, atai Life Sciences, Cybin, Beckley Psytech, Small Pharma, Usona Institute |
Moz Domain Authority 56/100 vs category average 37 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #297,261 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Compass Pathways has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Every journey needs a Compass. Advancing new options for people living with difficult-to-treat mental health conditions through rigorous science and compassion." (Meta description: 21 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Next.js, Cloudflare.
Social footprint: verified profiles on YouTube, X (Twitter), LinkedIn, Instagram, GitHub; no detected presence on Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Compass Pathways scores 62/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Compass Pathways has a moderate AI-visibility profile at 62/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (68/100) and its weakest is trust (52/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #297,261 (Tranco). The main gaps holding it back: no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Compass Pathways from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Compass Pathways?", Claude could identify the brand as of August 2026. Compass Pathways is a mental health care company developing psilocybin therapy, specifically COMP360, a synthetic psilocybin formulation being studied in clinical trials for treatment-resistant depression. Best known for Developing COMP360 psilocybin therapy for treatment-resistant depression.
When asked "Best brands similar to Compass Pathways?", Claude would recommend Compass Pathways as of August 2026. It's one of the most prominent and well-funded companies in the psychedelic medicine space, especially for psilocybin-based depression treatment.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Compass Pathways's main competitors include MindMed, atai Life Sciences, Cybin, Beckley Psytech, Small Pharma. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Popular alternatives to Compass Pathways include MindMed, atai Life Sciences, Cybin, Beckley Psytech, Small Pharma. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Compass Pathways is a British biotechnology company founded in 2016 and headquartered in London. It develops psilocybin-based treatments aimed at people living with difficult-to-treat mental health conditions.
Sources: Compass Pathways official site
Compass Pathways has moderate AI-search visibility, scoring 62/100 on Brand Analyzer's AI visibility composite (visibility 68, trust 52, recommendation 65). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Compass Pathways official site
Compass Pathways was founded in 2016. Compass Pathways operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Compass Pathways is headquartered in London. Compass Pathways operates in the Healthcare category.
Sources: Wikidata
Compass Pathways offers psilocybin-based treatments designed for people with difficult-to-treat mental health conditions, developed through rigorous scientific research as part of efforts to establish a new clinical standard in mental health care.
Sources: Compass Pathways official site
Compass Pathways and MindMed are competitors in Healthcare. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Compass Pathways develops psilocybin-based treatments for mental health disorders, using rigorous scientific research to create new therapeutic options for conditions that are difficult to treat with existing therapies.
Sources: Compass Pathways official site
Compass Pathways scores 65/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Compass Pathways official site
Compass Pathways can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Compass Pathways official site
Compass Pathways' work is intended for people living with difficult-to-treat mental health conditions, along with their caregivers and healthcare professionals who are seeking new treatment options for these conditions.
Sources: Compass Pathways official site
Compass Pathways is known for pioneering psilocybin-based treatment development for difficult-to-treat mental health conditions, positioning itself as a science-led company in the emerging psychedelic therapy space.
Sources: Compass Pathways official site
Ranked closest to Compass Pathways: Coloplast (86/100), CogniFit (86/100), Cooley (86/100), Center for Victims of Torture (86/100).
A step up - brands to learn from: theSkimm (91/100), Replika (91/100).
Category leader: Elsevier (96/100).